Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype
- PMID: 458558
- DOI: 10.1007/BF01059442
Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype
Abstract
The pharmacokinetics of procainamide was determined in 21 lidocaine-resistant patients who received the drug according to a pharmacokinetically designed double-infusion technique. Thirteen patients were phenotyped as slow acetylators, seven as fast, and one as intermediate. The total body clearances (ClT) of PA in slow and fast acetylators were 22.6 and 34.8 liters/hr, respectively. The fraction of PA cleared by the formation of NAPA in the corresponding acetylator group was 0.2 and 0.4. Renal impairment affected the pharmacokinetics of PA more profoundly as the ClT's of PA in patients with and without renal impairment were 17.9 and 31.2 liters/hr, respectively. None of the calculated volumes of distribution was affected by acetylator phenotype or renal impairment. These data identify the contribution of at least two of the major factors accounting for variability in PA disposition in patients undergoing therapy.
Similar articles
-
Genetically determined variability in acetylation and oxidation. Therapeutic implications.Drugs. 1985 Apr;29(4):342-75. doi: 10.2165/00003495-198529040-00003. Drugs. 1985. PMID: 2859977 Review.
-
[Pharmacokinetics of procainamide and its metabolite depending on acetylator phenotype].Pol Tyg Lek. 1992 Oct 5-12;47(40-41):921-3. Pol Tyg Lek. 1992. PMID: 1284448 Polish.
-
Kinetics of procainamide and N-acetylprocainamide in renal failure.Kidney Int. 1977 Dec;12(6):422-9. doi: 10.1038/ki.1977.133. Kidney Int. 1977. PMID: 609192
-
Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.Eur J Clin Pharmacol. 1983;25(6):791-5. doi: 10.1007/BF00542522. Eur J Clin Pharmacol. 1983. PMID: 6198178
-
Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias.Ann N Y Acad Sci. 1984;432:177-88. doi: 10.1111/j.1749-6632.1984.tb14519.x. Ann N Y Acad Sci. 1984. PMID: 6084435 Review.
Cited by
-
Drug metabolites in renal failure: pharmacokinetic and clinical implications.Clin Pharmacokinet. 1981 Sep-Oct;6(5):329-45. doi: 10.2165/00003088-198106050-00001. Clin Pharmacokinet. 1981. PMID: 7037261 Review. No abstract available.
-
Genetically determined variability in acetylation and oxidation. Therapeutic implications.Drugs. 1985 Apr;29(4):342-75. doi: 10.2165/00003495-198529040-00003. Drugs. 1985. PMID: 2859977 Review.
-
The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect.Pharm Res. 1991 Jan;8(1):25-32. doi: 10.1023/a:1015865920043. Pharm Res. 1991. PMID: 2014204
-
Population pharmacokinetics of procainamide from routine clinical data.Clin Pharmacokinet. 1984 Nov-Dec;9(6):545-54. doi: 10.2165/00003088-198409060-00004. Clin Pharmacokinet. 1984. PMID: 6509861
-
Clinical pharmacokinetics of N-acetylprocainamide.Clin Pharmacokinet. 1982 May-Jun;7(3):206-20. doi: 10.2165/00003088-198207030-00002. Clin Pharmacokinet. 1982. PMID: 6178545 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous